Abiopharma

🔍 Anthony Michele Marie (Executive)

Company: ORASURE TECHNOLOGIES INC (OSUR)

Report Date: 2026-03-01

Detailed Transactions and Holdings:

• Acquired 14,183 shares of Common Stock (Direct)
  Date: 2026-03-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 157,685.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 4,062 shares of Common Stock at $3.0425 per share (Direct)
  Date: 2026-03-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 153,623.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 10,817 shares of Common Stock at $3.0425 per share (Direct)
  Date: 2026-03-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 142,806.00 | transaction_form_type: 4 | Footnotes: F3
• Acquired 42,982 shares of Common Stock (Direct)
  Date: 2026-03-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 185,788.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: Shares delivered in settlement of vested performance units that did not constitute a derivative security.
• F2: Withholding of shares to pay tax liability associated with the vesting of performance units.
• F3: Withholding of shares to pay the tax liability associated with vesting of restricted shares.
• F4: Grant of restricted stock award vesting in three equal annual installments beginning on March 2, 2027, subject to the Reporting Person's continuous service through the applicable vesting dates.